GW Pharmaceuticals Plc ADS (GWPH)

[Cbdpotential]

In the NEWS

These developments mean that new markets for cannabis research, medical use, and recreational use will be opening up all the time. It only takes one company as industrious as Cannagrow to seize upon these new markets and elevate share value. Take for example GW Pharmaceuticals (NASDAQ:GWPH), which now trades at 71.34 after successfully developing a portfolio of cannibinoid treatments that includes Sativex, a cannabis-based drug that alleviates spasticity in Multiple Sclerosis and has been shown to help pain symptoms from cancer. Sativex is used in 15 different countries, and it appears to be only a matter of time before it makes its way to the U.S.